Pneumoconiosis Market Statistics Analysis 2020-2023

 Market Scenario:

Pneumoconiosis is a restrictive and occupational lung disease caused by inhalation of dust. There are a number of different agents that, when inhaled, can potentially cause pneumoconiosis. Organic and inorganic agents are responsible for causing this diseases. According to the Centers for Disease Control and Prevention, in 2013, 260,000 deaths occurred due to pneumoconiosis. Increasing prevalence of pneumoconiosis, increasing smoking population, and rising air pollution have driven the growth of the market. Approximately 75% of non-asbestos pneumoconiosis cases recorded under the IIDB scheme in 2009 were from individuals that are over 65 years. According to the Centers for Disease Control and Prevention, cigarette smoking is the leading cause of death in the United States, accounting for over 480,000 deaths every year. Moreover, increasing geriatric population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of pneumoconiosis; more than 60% of the global population smokes, this has increased the risk of pneumoconiosis and contributed in the growth of the market. However, side effects associated with the treatment and lack of long term treatment may lead to hinder the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4639

The global pneumoconiosis market is expected to grow at a CAGR of 6.8% during forecast period. 

Intended Audience

• Biotechnological institutes
• Pharmaceutical companies
• Government and Private Laboratories
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Medical Research Laboratories

Segmentation

The global pneumoconiosis market is segmented on the basis of types, causes, therapy, and end users.

On the basis of types, the market is segmented into asbestosis, berylliosis, byssinosis, coal workers pneumoconiosis, silicosis, and others.

On the basis of causes, the market is categorised into organic dusts, non-organic substances, and others. Organic substances are further segmented into hay, malt, mushrooms, and others. Non organic substances are further segmented into sulphur dioxide, ammonia, nitrogen dioxide, and others.

On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest X-ray, CT scan, and others. Treatment is further classified into mucolytic agent, antibiotic, and others.

On the basis of end users, the market is segmented into hospital, clinics, and others.

Regional Analysis

America dominates the global pneumoconiosis market owing to large patient population. Apart from this, increasing number of patients, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention, in 2015, about 15 in every 100 U.S. adults aged over 18 years smoked cigarettes. Which is equals around 36.5 million adults in the United States currently smoke cigarettes. Increasing smoking population increases the possibility of causing the disease. Additionally, increasing awareness among the people regarding different diagnostic procedures and well-developed technology has also contributed to the growth of the market.

Europe is the second largest pneumoconiosis market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.

Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and presence of huge opportunity in the market.

On the other hand, the Middle East & Africa has the least share in the global pneumoconiosis market due to presence of poor economy especially in Africa region. Majority of the market of this region is held by Middle East due to well-developed healthcare sector and huge healthcare expenditure. 

Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation 

Key players for global pneumoconiosis market

The key players for the global pneumoconiosis market Abbott (US) Eli Lilly (U.S.), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), and Bayer Cropscience Ltd. (U.S.).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/pneumoconiosis-market-4639

Labyrinthitis Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and Forecast Research Study 2023

 Labyrinthitis, also known as vestibular neuritis, is an inflammation of the inner ear or the nerves that connect the inner ear to the brain due to a variety of reasons such as infection by measles, mumps, trauma, autoimmune etc. Labyrinthitis shows various symptoms such as hearing loss, speech problems, double vision, abnormal gait, dizziness, nystagmus (rapid and undesired eye motion), vertigo, ringing in the ears, etc. Labyrinthitis is triggered by cold flu and occur as a single attack, or a series of attacks, which generally resolves on its own over three to six weeks.

The causes of labyrinthitis are upper respiratory infection such as common cold or flu, infection by herpes simplex type 1 virus, acute localized ischemia, pressure changes such as while flying or scuba diving, etc. Labyrinthitis affects approximately 35 cases per 1 million people per year across the globe and it is rising due to growing exposure to pathogenic agents. Labyrinthitis affects older population to a greater degree due to weak immunity and hearing problems.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4623

Rising older population, increasing awareness and screening, developing healthcare and ENT centres, developing new drugs, especially the advancements in antibiotics are driving the market growth. Development of selective antibiotics for ear and nose infections such as streptomycin has driven the market growth. On the other hand, side effects and high cost of treatment and misdiagnosis may hinder the growth of the labyrinthitis market over the review period.

The global labyrinthitis market is expected to reach USD 2.5 billion by 2023 at a CAGR of ~ 3.2% during the forecast period 2017-2023.

Segments

The global labyrinthitis market has been segmented on the basis of types, diagnosis, treatment, and end user.

Based on the types, the market has been segmented as autoimmune labyrinthitis, infective labyrinthitis, and other.

Based on the diagnosis, the market has been segmented as physical examination, blood test, magnetic resonance imaging and computed tomography, electroencephalogram (EEG) and electronystagmography (ENG) and others.

Based on the treatment, the market has been segmented as antihistaminics and antiemetics, antibiotics, corticosteroids, and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.

Regional Analysis

The Americas accounts for a significant market share owing to high expenditure on the health care. Additionally, the fastest uptake of new diagnostics and drugs in the US drives the labyrinthitis market. Furthermore, concentration of the major healthcare companies and large hospitals in the developed countries of this region coupled with large insurance penetration are adding fuel to the market growth. The US expend high amount on its healthcare in 2015, which accounted for 16% of total GDP which, in turn, likely to drive the labyrinthitis market.

Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period. However the southern European nations have witnessed a greater incidence of infective labyrinthitis due to associated environmental conditional. Owing to strong pharmaceutical industry, Germany dominates the Europe market.

Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. Furthermore, growing penetration of healthcare insurance in the Asia Pacific region is expected to drive the future labyrinthitis market in the region.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt, and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development. However the poor countries and developing regions have the greatest unmet needs, which needs to be tapped.

Key Players in the Global Labyrinthitis Market

Some of the key players profiled in the report are Merck & Co., Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Shandong Taihua Bio &Tech Co., Cipla Inc., and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/labyrinthitis-market-4623

Gingivostomatitis Market Revenue and Value Chain 2020-2023

 Diabetes is a metabolic disorder in which the body glucose level is elevated. Gestational diabetes is a temporary or permanent form of diabetes in which the body does not produce adequate amounts of insulin to regulate sugar during pregnancy. It may also be called glucose intolerance or carbohydrate intolerance. According to the International Diabetes Federation in 2016, it was estimated that 420 million adult population is suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. According to the American Pregnancy Association, approximately 2-5% of pregnant women develop gestational diabetes; this number may increase to 7-9% of mothers who are more likely to have risk factors. Increasing prevalence of the gestational diabetic population is the major driving factor for the growth of the market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market. However, lack of awareness among people and cost issues may lead to restrain the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4591

The global gestational diabetic market is expected to grow at a CAGR of 5.4% during forecast period. 

Intended Audience

• Biotechnological institutes
• Pharmaceutical companies
• Government and Private Laboratories
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Medical Research Laboratories 

Segmentation

The global gestational diabetes market is segmented on the basis of types, administration, treatment, and end users.

On the basis of types, the market is segmented into type A1, type A2 and others.

On the basis of administration, the market is categorised into oral, intravenous, and other.

On the basis of treatment, the market is segmented into monitoring, drug treatment, and non-pharmacological treatment. Monitoring is further segmented into urinary glucose testing, oral glucose tolerance test, and others. Drug treatment is subsegmented into insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, and others

On the basis of end users, the market is segmented into hospital, retail pharmacy and other.

Regional Analysis

America dominates the global gestational diabetes market owing to large patient population. Apart from this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US were diagnosed with high cholesterol level. Increasing cholesterol level and smoking increases the possibility of causing diabetes. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.

Europe is the second largest gestational diabetes market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.

Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and increasing need for the better treatment.

On the other hand, the Middle East & Africa has the least share in the global gestational diabetes market due to presence of poor economy especially in Africa region. Majority of the market of this region is hold by Middle East due to well-developed healthcare sector and huge healthcare expenditure.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/gestational-diabetes-market-4591

Gingivostomatitis Market: Recent Industry Trends and Projected Industry Growth, 2020– 2023

 Market Scenario

Gingiva means gums and stomata refers to mouth. Gingivostomatitis is a combination of gingivitis and stomatitis, which is the inflammation of the oral mucosa and gingiva. Gingivostomatitis is most commonly caused by herpes simplex virus type 1 (HSV-1), coxsackievirus, bacteria such as Streptococcus, Actinomyces etc. Poor oral hygiene is an important risk factor for Gingivostomatitis. Symptoms of gingivostomatitis may include tender sores on the gums or cheeks, bad breath, fever, swollen gums and lymph nodes, bleeding, difficulty in eating etc. Gingivostomatitis is a common infection of the mouth and gums and frequently occurs in children. If left untreated complications such as severe mouth ulcers can occur. Gingivostomatitis is caused in 90% of cases by herpes simplex virus type 1. Acyclovir and penciclovir are the drugs of choice for the treatment of herpes simplex virus type 1, but microbial resistance has been on a rise which has led to high degree of clinical failures. Thus there is an unmet need for a new drug with selectivity and lethal action against of herpes simplex virus. Development of any new drug for the treatment of herpes simplex virus will be met with great market enthusiasm with a minimum of marketing costs and efforts. The rising use of oral hygiene products, availability of broad spectrum antibiotics and oral products, rising dentistry healthcare facilities, good rate of reimbursements etc.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4402

Product development represents the best strategy for development of the market. Advanced broad spectrum antibacterial mouth rinses, improving palatability and quality of oral hygiene products etc. will drive the future growth of the market. The developing regions of Asia and Middle East provide ample growth space for new players as there is comparatively less competition in these regions for the oral hygiene product. The market drivers for Gingivostomatitis market are, increase in risk factors such as fatty and sugar rich foods, growing screening, increasing child and infant population etc. The market restraints are complications and risk of the surgery, lack of awareness and misdiagnosis, etc.

The global Gingivostomatitis market is expected to reach USD 15.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 6.6 % during the forecast period 2017-2023.

Segments:

The global Gingivostomatitis market has been segmented on the basis of diagnosis, treatment, and end user.

Based on diagnosis, the market has been segmented as physical examination, microbial culture, biopsy and others.

Based on treatment, the market has been segmented as non-steroidal anti-inflammatory drugs, antiviral and antibacterial, debridement of the mouth and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research and others.

Regional Analysis:
The Americas accounted for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new products in the US drives the Gingivostomatitis market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger market for oral hygiene products is adding fuel to the market growth. The large expenditure by the US on healthcare accounting to 16% of GDP also cruises the sale of Gingivostomatitis treatment.

Europe is the second largest market in the world due to high income and healthcare penetration. Europe is led by countries such as Germany and France. UK is expected to be the fastest growing market. The large influence of media and the rise in awareness of oral hygiene coupled with the high per capita income of the population drives the European market for Gingivostomatitis.

Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asia countries such as Vietnam, Thailand and Malaysia will also contribute highly to the market.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. However it has to be noted that Africa has the highest unmet needs in the world and cost effective products will be the key to dominate the African market. First comer advantage and established dominance in African market are advantages that will be difficult to overcome by any new player due to the smaller market size and market value of the African market for Gingivostomatitis.

Key Players in the Global Gingivostomatitis Market
Some of key players profiled in the report are Pfizer Inc., Taj Pharmaceutical limited., Ciron pharma, Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc. Novartis, F. Hoffman La Roche AG, Eli Lily and Company, AstraZeneca Plc., and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/gingivostomatitis-market-4402

EMEA Gastrointestinal Drugs Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and Forecast Research Study 2023

 Market Scenario:

Gastrointestinal (GI) drug market is a growing market in Europe and Middle East and Africa. As per study it was estimated that ~ 6% of total European population is suffering from minor or major gastrointestinal problems. Gastroesophageal reflux is the most common disease and is responsible for generating a good market. The major driving factor for this market are increasing prevalence of many gastrointestinal disease. In addition to this, technological advances, infrastructure development increasing investment in research activity and increasing awareness about the availability of treatment are responsible for providing fuel for the growth of the market. While incorrect self-diagnosis and availability of many misbranded drug are the major restraining factor for the growth of market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/608

Europe and Middle East and Africa GI drug market is expected to grow at a CAGR of 4.5% during 2017-2023.

Key Players for Europe, Middle East and Africa Gastrointestinal Drugs market

AstraZeneca Plc.(UK), Johnson & Johnson (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals Inc. (US), Sanofi Ltd. (France), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), AbbVie Inc. (US), Janssen Biotech (US), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany).
Segmentation
Europe, Middle East and Africa gastrointestinal drugs market has been segmented on the basis of Drug Category they are segmented into Acid Neutralizers, Laxatives and Antidiarrheal, antiemetic, Anti-inflammatory drugs and other. Acid Neutralizers are further sub segmented into Antacids, H2 antagonists, Proton pump inhibitors and others. By Route of Administration they are segmented into Oral, Parenteral and rectal. By disease type they are segmented into Gastroesophageal Reflux Disease, Inflammatory Bowel Disease and Other. By End User Hospital Pharmacies, Retail Pharmacies and Other

Regional Analysis
Europe is the second major contributor in the GI drug market globally. Total Europe and Middle East and Africa GI drug market in 2016 was approximately USD$ 15 million. Germany and France are the major contributor of the market this is due to a huge number of patient suffering from different GI problems. About 9.2% of total population in France is suffering from acute or chronic GI problems. This is the major factor responsible for the growth of market. Due to saturation of market in this region the market is growing at a steady CAGR of 4.5 % during 2017-2023.

The report for Europe, Middle East and Africa Gastrointestinal Drugs Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/europe-gastrointestinal-drugs-market-608

APAC Gastrointestinal Drugs Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2023

 Market Scenario

Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, esophagus, liver, gallbladder, and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation, and many more. The diseases of gastrointestinal have become common in the people across world.  Gastrointestinal diseases are caused by various reasons such as acid reflux, heartburn, indigestion, nausea and vomiting, peptic ulcer disease, abdominal pain syndrome, biliary tract disorders, gallbladder disorders, and gallstone pancreatitis.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/633

Gastrointestinal diseases has gained a tremendous attention over the last few years. Owing to increasing prevalence of different gastrointestinal diseases and disorders, encouraged many companies for initiating the research in the development of innovative and advanced drugs. Furthermore, increasing prevalence of GI diseases, rising geriatric population, and increasing investment in research & development drives the growth of the market. Additionally, changing lifestyle and increasing awareness about the availability of the treatment fuel the market growth.

From the few last decades, the government of Asian countries have been educating the people about the various diseases and their treatment availability. Relief International, with funding from the European Union, is working with Bangladesh citizens to implement One Health Asia, a program designed to prevent zoonotic diseases through training and education. Many organizations and companies are conducting surveys and programs to educate the peoples about the diseases and treatment.

Ageing, decreases the immunity of the body and increases the probability of diseases. According to Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, approximately 12.4% of the population in the region was over 60 years. According to Asian Development Bank, it was estimated that by 2050, 15% of total Malaysian population will be over 65 year old and in China, the elderly population will reach over 300 million by 2050. Thus, the increasing geriatric population in Asia likely to help the growth of the market over the forecast period.

On the other hand, the presence of misbranded & spurious drugs, and unavailability of lifelong cure may hinder the market growth over the review period.  

The Asia gastrointestinal drugs market is expected to grow at a CAGR of 6.1% during the forecast period 2017-2023.

Research Methodology

Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation 

Segmentation
The Asia gastrointestinal drugs market is segmented on the basis of drug class and type of disease.

On the basis of drug class, it is segmented into acid neutralizers, laxatives & antidiarrheal, antiemetics, antiulcer, and others.

On the basis of type of disease, it is segmented into esophagus diseases, stomach diseases, intestinal diseases, rectum diseases, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/asia-pacific-gastrointestinal-drugs-market-633

EPharmacy Market : The report gives immense knowledge on the competitive nature of key players 2027

 Global ePharmacy Market was valued at USD 62,587.0 Million in 2019 and is expected to register a CAGR of 12.5% during the forecast period of 2020 to 2027.

An E-Pharmacy is a pharmacy that operates over the internet and sends orders to customers through mail or shipping companies. The growth of the online pharmacies can be acknowledged from the following examples. The electronic prescription service (EPS) was aimed at rolling out in November 2019, according to the Department of Health, UK, claiming it would save the NHS through increasing efficiencies, reducing the amount of paper processing required, and reducing prescribing errors. In January 2019, Ping An Good Doctor, a one-stop healthcare ecosystem platform from China, announced that it had placed its One-minute Clinics across 8 provinces and cities in China and signed service contracts for nearly 1,000 units, providing healthcare services to more than 3 million users. Every One-minute Clinic has more than 100 categories of common drugs, all of which are cryogenically refrigerated to ensure their quality. New York in 2016 took the step of requiring prescribers to use electronic transmission of prescriptions to pharmacies.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6615 

Factors such as the convenience provided in the delivery of medication discounted price, and laws favoring the adoption of ePharmacy, are driving the growth of the ePharmacy market. Additionally, rising investment for small companies is also driving the growth of the ePharmacy market. However, the rising number of counterfeit online pharmacies is posing as a challenge for the growth of the market.

Segment Analysis

Global ePharmacy Market has been divided based on drug Type, Operating Platform, and Business Model.

The market, based on drug type, has been segregated into prescription drugs and over the counter (OTC) drugs.

Based on operating platform, the ePharmacy market has been divided into app and websites.

On the basis of business model, the ePharmacy market is segregated into the marketplace, pharmacy, and direct.

Regional Analysis

The global ePharmacy market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is likely to hold the largest share of the global ePharmacy market during the assessment period owing to the presence of a large number of ePharmacy in the region. Some of the renowned ePharmacy in the region include Walgreens Boots Alliance, Inc., Wal-Mart, Inc., CVS Health, PillPack, Inc., and others. According to a 2019 survey, 19% of health care providers in the U.S. offer a customer’s web-based prescription refill online program. It was also reported that several retail pharmacies have been offering mobile apps for an online prescription refill. A large number of companies such as Walgreens and CVS Pharmacy offer mobile apps to make prescription refill easy and convenient with a round to clock delivery. The ePharmacy market in Europe is expected to propel during the forecast period, owing to factors such as rising government initiatives, increasing awareness among customers regarding ePharmacy, and the convenience associated with the offered services. The fast growth of the Asia-Pacific region is due to rising investment for ePharmacy startups and the increasing per capita income along with government initiatives to enhance the quality of healthcare. China, India, and Australia have a lucrative market for ePharmacy due to the growing investment. The online pharmacy market in India attracted funding of USD 93 million by 2015. As a result, 60 online pharmacy start-ups emerged in 2017.

Key Players

MRFR recognizes the following companies as the Key Players in the Global ePharmacy Market— Walgreens Boots Alliance, Inc., Wal-Mart, Inc., CVS Health, Dr. Fox Pharmacy, DocMorris N.V., Rowlands Pharmacy, OptumRx, The Online Drugstore, Well Pharmacy, LloydsPharmacy and Others.

Key Findings of the Study

• The Global ePharmacy Market was valued at USD 62,587.0 Million and is expected to register a CAGR of 12.5% during the assessment period

• The Americas accounted for the largest share of the global market due to the increasing preference of customers to buy medications online and growth in the number of ePharmacy. These factors are driving the growth of the ePharmacy market in the region

• Based on the drug type, the prescription drugs segment accounted for the largest market share of 55.6% in 2019

• Based on the operating platform, the app segment accounted for the largest market share of 57.6% in 2019

• Based on the business model, the marketplace segment accounted for the largest market share with a value of USD 28,813.3 Million in 2019

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/epharmacy-market-6615